This approval covers Wave 2 of PATH. A full revision is necessary for the collection of Wave 3 data. Before submitting the information collection request for Wave 3 to OMB, NIDA/FDA should report to OMB regarding: a) the response rates associated with the full baseline wave, including screening, interview completion, and bio-specimen response; b) Wave 2 retention, recruitment rates for the âage in to adultâ and âage in of shadowâ subsamples; c) the results of nonresponse analysis and statistical approach for addressing non-response, as well as implications for the study going forward; and d) the statistical approach to be applied to the bio-specimen data to address potential non-response bias from lower consent and cooperation rates with this aspect of the study.
Per prior terms of clearance, NIDA and FDA will create a public use dataset from each waveâs data, making it available to the public on-line within 18 months of completion of each wave. Data underlying government-funded scientific publications will be made available to the public, consistent with NIH guidelines for implementing OSTPâs Public Access to the Results of Federally Funded Research.
This study is not specifically designed to provide nationally representative estimates of prevalence. As such, FDA and NIDA will always present such cross-sectional prevalence estimates in conjunction with estimates from HHSâ signature nationally representative studies such as CPS-TUPS, NHIS, NATS, and NSDUH.
Inventory as of this Action
Requested
Previously Approved
09/30/2016
36 Months From Approved
11/30/2015
193,243
0
546,222
56,939
0
132,620
0
0
0
This is a revision request (OMB 0925-0664, expires 11/30/2015) for the Population Assessment of Tobacco and Health (PATH) Study to conduct the second wave of data collection. The PATH Study is a national longitudinal cohort study on tobacco use behavior, attitudes, and health among the U.S. household population of adults age 18 and older and youth ages 12 to 17. The PATH Study conducts annual interviews and collects biospecimens from adults to measure and report within-person changes and between-person differences in tobacco product use behaviors, attitudes, and health effects within the cohort over time. Data from the PATH Study will enhance the knowledge base that informs FDA's regulatory decisions and actions under the 2009 Family Smoking Prevention and Tobacco Control Act (TCA). The TCA authorized FDA to regulate tobacco products, including tobacco-product advertising, labeling, marketing, constituents, ingredients, and additives.
US Code:
42 USC 285o
Name of Law: Public Health Service Act
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.